Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance

Value in Health

Volumn 12, Issue 2, 2009, Pages 234-244

  Jansen, Jeroen P ^a   Kumar, Ritesh ^b   Carmeli, Yehuda ^c  

^a MAPI VALUES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Antimicrobial resistance; Compartment model; Cost effectiveness; Intraabdominal infections

Indexed keywords

ERTAPENEM; PIPERACILLIN; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; PENICILLANIC ACID;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE MODEL; DRUG EFFICACY; DRUG ELUTING STENT; ERADICATION THERAPY; HUMAN; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; ABDOMINAL ABSCESS; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG COST; ECONOMICS; EVALUATION STUDY; MULTIDRUG RESISTANCE; PERITONITIS; STATISTICAL MODEL; SURGICAL WOUND INFECTION;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MODELS, ECONOMIC; NETHERLANDS; PENICILLANIC ACID; PERITONITIS; PIPERACILLIN; QUALITY-ADJUSTED LIFE YEARS; SURGICAL WOUND INFECTION;

EID: 60349115429     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00439.x     Document Type: Article

References (31)

1. Solomkin JS, Hemsell DL, Sweet R, et al. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious diseases society of America and the Food and Drug Administration. Clin Infect Dis 1992 15 (Suppl. S33 42.
2. Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992 127 : 83 9.
3. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003 37 : 997 1005.
4. Lorber B, Swenson RM. The bacteriology of intra-abdominal infections. Surg Clin North Am 1975 55 : 1349 54.
5. Bartlett JG, Onderdonk AB, Louie T, et al. A review. Lessons from an animal model of intra-abdominal sepsis. Arch Surg 1978 113 : 853 7.
6. Nichols RL, Muzik AC. Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992 15 : 72 6.
7. Pacelli P, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996 131 : 641 5.
8. Christou NV, Turgeon P, Wassef R, et al. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broadspectrum antibiotic coverage. Arch Surg 1996 131 : 1193 201.
9. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003 237 : 235 45.
10. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Infect Dis 1983 5 : 1033 48.
11. Cohen FL, Tartasky D. Microbial resistance to drug therapy: a review. Am J Infect Control 1997 25 : 51 64.
12. Hanberger H, Hoffmann M, Lindgren S, et al. High incidence of antibiotic resistance among bacteria in four intensive care units at a university hospital in Sweden. Scand J Infect Dis 1997 29 : 607 14.
13. Muder RR, Brennen C, Drenning SD, et al. Multiply antibioticresistant gram-negative bacilli in a long-term-care facility: a case control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997 18 : 808 13.
14. Hopkins JA, Lee JC, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg 1993 59 : 791 6.
15. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000 45 : 183 9.
16. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001 39 : 2206 12.
17. Mouton J, Voss A, Arends J, Bernard S. Prevalence of ESBL in the Netherlands: the ONE study. 17th European Congress of Clinical Microbiology and Infectious Diseases ICC, Munich, Germany, 31 Mar-04 Apr 2007.
18. Gallagher G, Hsueh PR, Baquero F, et al. Worldwide antimicrobial susceptibility patterns among E. coli isolated from intra-abdominal infections (IAI): results from SMART 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases ICC, Munich, Germany, 31 Mar-04 Apr 2007.
19. Dinubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005 24 : 443 9.
20. Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics 1999 16 : 551 61.
21. Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Manage 2001 42 : 183 206.
22. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. PNAS 2000 97 : 1938 43.
23. Bruinsma N, Hutchinson JM, Van den Bogaard AE, et al. Influence of population density on antibiotic resistance. J Antimicrob Chemother 2003 51 : 385 90.
24. Levin BR. Minimizing potential resistance: a population dynamics view. Clin Infect Dis 2001 33 (Suppl. 3 S161 9.
25. Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intra abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005 60 : 438 43.
26. Dietrich ES, Schubert B, Ebner W, Daschner F. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection. Pharmacoeconomics 2001 19 : 79 94.
27. Krobot KD, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004 23 : 682 87.
28. Davey P, Libby G, Hunter K, et al. How important is appropriate empirical antibiotic treatment for intra-abdominal infections? ISPOR 6th Annual International Meeting. Virginia USA, 2001.
29. Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006 7 : 72 8.
30. Dela Pena S, Asperger W, Kockerling F, et al. Efficacy and safety of ertapenem versus piperacillin/tazobactam for the treatment of intra-abdominal infections requiring surgical interventions. J Gastrointest Surg 2006 10 : 567 74.
31. Namias N, Solomkin JS, Jensen EH, et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 2007 8 : 15 28.